Schering Sales Corp. to pay $435m in settlement

Share this article:
Schering Sales Corp., a division of Schering-Plough, will pay $435 million in connection with Medicaid fraud and illegal sales and marketing programs under a Jan. 17 court sentence.

A suit brought by the FDA and other agencies charged the company with making false statements to government agencies to hide its illegal off-label promotion of Temodar for use in treating brain tumors and metasteses and Intron A for use in treating superficial bladder cancer.

The suit also said Schering concealed its best price on Claritin RediTabs to avoid paying millions of dollars in additional Medicaid rebate liabilities.

The company pleaded guilty last September to criminal charges of making false statements to the FDA and to the HHSs. The company was sentenced to pay a $180 million criminal fine on those charges.

Schering pleaded guilty to conspiring with others to make false statements to the FDA in response to another inquiry by the agency.  

Share this article:
close

Next Article in News

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...